Tests deucravacitinib for skin patches in teens with psoriasis
Tests deucravacitinib against placebo in teens with moderate to severe plaque psoriasis.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Key facts
- Where
- Bayamón, Caguas, and San Juan, Puerto RicoSee the 3 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 17 years old?
Source: NCT06979453, who can take part
Where in Puerto Rico
- BayamónBayamón, Puerto RicoNot yet recruiting
- CaguasCaguas, Puerto RicoNot yet recruiting
- GCM Medical Group, PSC - Hato Rey SiteSan Juan, Puerto RicoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06979453EU 2023-506296-97-00
- Record updated
- 27 October 2026
- Original description
The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasisRead full original descriptionShow less
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 Years to Less Than 18 Years) With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis
Inclusion: Participants must have stable plaque psoriasis for 6 months or more prior to Screening; Participants must have moderate to severe psoriasis defined by:; Psoriasis Area and Severity Index (PASI) ≥ 12, at screening visit and Day 1; Static Physician's Global Assessment (sPGA) ≥ 3, at screening visit and Day 1; Body Surface Area (BSA) ≥ 10% involvement, at screening visit and Day 1; A female (as assigned at birth) participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:; Is not an individual of childbearing potential (IOCBP); Is an IOCBP and using a contraceptive method that is highly effective (with a failure rate of < 1% per year) during the study intervention period and for at least 3 days after discontinuation of the study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction for the same period.
Exclusion: Participants must not have a history of serious bacterial, fungal, or viral infection requiring hospitalization and intravenous (IV) antimicrobial treatment within 60 days prior to Day 1; Participants must not have any untreated bacterial infection within 60 days prior to Day 1; Participants must not have received live vaccines or BCG within 60 days prior to Day 1 or plans to receive a live vaccine during the study, or within 60 days after completing study intervention; Participants must not have had any prior exposure to deucravacitinib; Participants must not have received any medication that is specifically prohibited; Participants must not have non-plaque psoriasis (ie, guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis) or any skin condition other than plaque psoriasis that could interfere with assessments of treatment effect at Screening or Day 1; Participants must not have any ongoing evidence of chronic bacterial infection (eg, chronic pyelonephritis, chronic osteomyelitis, chronic bronchiectasis); Participants must not have herpes simplex/zoster, active tuberculosis (TB), hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV) infection-related exclusions; Participants must not have any major illness/condition or evidence of an unstable clinical condition (eg, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, psychiatric, neurologic, immunologic, or local active infection/infectious illness) that, in the investigator's judgment or after consultation with the Sponsor's Medical Monitor, will substantially increase the risk to the participant if he or she participates in the study; Participants must not have cancer or history of cancer (solid organ or hematologic including myelodysplastic syndrome) or lymphoproliferative disease within the previous 5 years; Participants must not have a laboratory finding that is exclusionary; Participants must not weigh < 30.0 kg at Screening and Day 1; Other protocol-defined Inclusion/Exclusion criteria apply.